Theoretical Problems of Legal Regulation of Innovations in the Medical Field: Experience in Counteracting Covid-19
Keywords:
Innovation, Coronavirus, Intellectual Property, Health, TRIPS Agreement
Abstract
The work is devoted to identifying the main problems of legal regulation of innovations in the medical field and developing the best options for solving them in the context of the Covid-19 pandemic. Thus, the research methodology is based on general and special scientific methods, in particular: formal legal, historical and legal, comparative analysis, and modeling. So, the procedure and issues to be considered are as follows. In the introduction, we will briefly highlight the origins of intellectual property rights issues in the medical field and the overall state of the pharmaceutical industry. In the first subsection of the third section, we will consider the positions of the main players in the pharmaceutical industry and the contradictions between them. In the second subsection, we will highlight the international obligations under TRIPS. In the third subsection, we will consider the consequences of their direct violation. In the fourth subsection, the impact of Covid-19 and the methods of legal regulation of medical innovations and patents under the TRIPS agreement will be discussed. In the fifth subsection, we will propose a way out and a compromise according to the Indian scenario. As a result of the study, contradictions were identified in the aspect of maintaining the balance of private and public interests between states and international pharmaceutical companies in the context of a pandemic and proposed ways to resolve them within the existing legal methods under the TRIPS agreement to achieve an acceptable compromise.
Downloads
Download data is not yet available.
References
Agencia Tributaria. (n.d.). Analysis of the EU Regulation n° 608/2013 of 12 June 2013 on customs enforcement of intellectual property rights, which repeals Council Regulation (EU) n° 1383/2003. Analysis of the implementation Regulation of the European Commission n° 1352/2013. In https://ukrpatent.org/i_upload/file/02-Training-of-customs-officials-Regulation-052016.pdf.
Buletsa, S. B. (2020). Features of the contract of controlled access in the conditions of Covid-19. In http://dspace.onua.edu.ua/handle/11300/12616.
Canada. Supreme Court. (2017). AstraZeneca Canada Inc. v. Apotex Inc.: Judgment. In https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/16713/index.do.
Chepis, O. I. (2020). Ensuring the balance of interests of right holders and society in the application of compulsory licensing in the conditions of Covid-19. In http://dspace.onua.edu.ua/handle/11300/12616.
Chibisov, D. M. (2017). Protection of intellectual property rights within the World Trade Organization. Odesa: Phoenix. In http://hdl.handle.net/11300/7382.
Chirikhin, S. N. (2009). Is the rise in drug prices again the fault of the monopolies? All-Russian economic journal ECO, 1, 36-50. https://cyberleninka.ru/article/n/vzlet-tsen-na-lekarstva-opyat-vina-monopoliy/viewer.
Curia Europa (2020). PTC Therapeutics International v. EMA; MSD Animal Health Innovation and Intervet International v. EMA. In http://curia.europa.eu/juris/document/document_print.jsf?docid=222504&text=&dir=&doclang=EN&part=1&occ=first&mode=lst&pageIndex=0&cid=1853575.
Davis, M. M., Zimmerman, J. L., Wheeler, J. R. C. & Freed, F. L. (2002). Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations. American Journal of Public Health, 92(12), 1982-1987. In https://www.immunize.ca/sites/default/files/resources/702e.pdf.
Delo.UA. (2016). Pharmacy chains create a monopoly, and 80% of drug supplies to Ukraine are controlled by 3 distributors. In https://delo.ua/business/aptechnye-seti-sozdajut-monopoliju-a-80-postavok-lekarstv-v-ukra-325399/.
Ennan, R.E. (2020). Methods of treatment as objects of patent law: world experience. Problems of legal regulation of civil relations in terms of Covid-19, 1, 41-45. In http://dspace.onua.edu.ua/handle/11300/12616.
European Commission (2001). Directive 2001/83/EC. In https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf.
European Parliament (2004). Regulation (EC) n° 726/2004. In https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32004R0726.
Ezekiel, L. E. (2019). Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up. The Atlantic. In https://www.theatlantic.com/health/archive/2019/03/drug-prices-high-cost-research-and-development/585253/#:~:text=Many%20drugs%20cost%20more%20than,which%20there%20are%20definitive%20data.
Ferrario, A. & Kanavos, P. (2013). Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMiNet. 2013. In http://eprints.lse.ac.uk/50513/.
Ferrario, A., Araja, D., Bochenek, T., Catic, T., Danko, D., Dimitrova, M., Furst, J., Greiciute-Kuprijanov, I., Hoxha, I., Jakupi, A., Laidmae11, E., Loblova, O., ´ Mardare, I., Markovic-Pekovic, V., Meshkov, D., Novakovic, T., Petrova, G., Pomorski, M., Tomek, D., Voncina, L., Haycox, A., Kanavos, P., Bonanno, P.V., Godman, B. (2017). The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. PharmacoEconomics, 35(1). DOI 10.1007/s40273-017-0559-4.
Finland & Ukraine. (2004). Treaty between the Government of Ukraine and the Government of the Republic of Finland on the promotion and mutual protection of investments. In http://search.ligazakon.ua/l_doc2.nsf/link1/MU04261.html.
Gilead Sciences Inc. v. Ukraine. (1996). In https://arbitration.org/award/688.
Global Affairs Canada. (2013). Eli Lilly and Company v. Government of Canada. In https://www.international.gc.ca/trade-agreements-accords-commerciaux/topics-domaines/disp-diff/eli.aspx?lang=eng.
Gritsyk, A. R. & Stasiv, T. G. (2006). The method is the main object of patent law in the pharmaceutical industry. Problems of modern medical science, 1, 45-48.
Heckman, A. (2017). Supreme Court of Canada Rejects the Promise of the Patent Doctrine. Gowling WLG. In https://gowlingwlg.com/en/insights-resources/articles/2017/promise-of-the-patent-doctrine/.
Higgins-Dunn, N. (2020). House report accuses Trump administration of ‘waste, fraud or abuse’ in U.S. ventilator contract. CNBC. In https://www.cnbc.com/2020/07/31/coronavirus-house-report-accuses-trump-administration-of-waste-fraud-or-abuse-in-us-ventilator-contract.html.
In the Matter of C & W’s Application for a Patent. Reports of Patent. (1914). Design and Trade Mark Cases, Volume 31(9), 235-236. DOI 10.1093/rpc/31.9.235.
India. (1970). Patent Act. In http://ipindia.nic.in/writereaddata/Portal/ev/sections/ps3.html.
Interfax Ukraine. (2018). PJSC “Farmak” supported the resolution to support the draft law n° 9385. In https://interfax.com.ua/news/press-release/555670.html.
Interfax Ukraine. (2020). Top 10 largest pharmacy chains will consolidate up to 70% of the market over the next few years–forecast. In https://interfax.com.ua/news/pharmacy/666614.html.
Interfax-Ukraine. (2020). Compulsory licensing of drugs to combat coronavirus can be a “Pandora’s box” for the pharmaceutical market–a lawyer. In https://ua.interfax.com.ua/news/pharmacy/651558.html.
Jorge, M. (2020). Opinion: Big pharma is taking big money from U.S. taxpayers to find a coronavirus vaccine—and charge whatever they want for it. Market Watch. In https://www.marketwatch.com/story/big-pharma-is-taking-big-money-from-us-taxpayers-to-find-a-coronavirus-vaccine-and-charge-whatever-they-want-for-it-2020-06-24.
Joshi Attorneys. (2020). Changes in India’s Patent Law. In https://www.joshiattorneys.com/Cross-Border-And-International-Law-Topics/In-the-Shadows.shtml#:~:text=However%2C%20since%201970%2C%20India%20has,molecule % 20yields% 20a% 20new% 20patent.
Kaiser Family Foundation (2015). Most Say They Can Afford Their Prescription Drugs, But One in Four Say Paying is Difficult, Including More Than Four in Ten People Who are Sick. In https://www.kff.org/health-costs/press-release/most-say-they-can-afford-their-prescription-drugs-but-one-in-four-say-paying-is-difficult-and-more-than-four-in-ten-for-people-who-are-sick/.
Kashintseva, O. Y. (2017). Compulsory licensing of medicines: EU experience. Theory and practice of intellectual property, 3, 38-42. In http://www.inprojournal.org/wp-content/uploads/2017/10/Kashyntseva-O._317.pdf
Kharytonova, O. I. (2020). On the use of off-label drugs (out of instructions) and compassionate use (for reasons of humanity), Covid-19, and new opportunities and challenges in the context of intellectual property protection. In http://dspace.onua.edu.ua/handle/11300/12616.
Kirichenko, I. A. (2020). Forced import substitution, or where does TRIPS + lead? Lexology. In https://www.lexology.com/library/detail.aspx?g=fb95962d-a6d5-4b0a-b36f-63ae203c9f91.
Kirsanov, D. (2020). Pharmacy market of Ukraine. Helicopter View. In https://www.apteka.ua/article/531429.
Kuchler, H., Inagaki, K. & Neville, S. (2020). The global hunt for a coronavirus drug. Financial Times. In https://www.ft.com/content/91bd081e-6e7b-11ea-9bca-bf503995cd6f.
Kuzmenko, L.G. (2016). Parallel imports—an important mechanism for the existence of competitive relations. Scientific notes of NaUKMA. Economic Sciences, 1(1), 95-100. In http://ekmair.ukma.edu.ua/bitstream/handle/123456789/14668/Kuzmenko_Paralelnyi_import_vazhlyvyi_mekhanizm.pdf?sequence=1&isAllowed=y.
Kyrychenko, I. (2020). Parallel import as a portal to the parallel world. Apteka online. In https://www.apteka.ua/article/534838.
Lupkin, S. (2020). Prices for Covid-19 Vaccines are starting to come into Focus. Health News from NPR. In https://www.npr.org/sections/health-shots/2020/08/06/899869278/prices-for-covid-19-vaccines-are-starting-to-come-into-focus.
Marsh, T. (2020). Here’s How to Get Discounted (Or Even Free) Flu Shots This Year. Goodrx. In https://www.goodrx.com/blog/heres-how-to-get-discounted-or-even-free-flu-shots-this-year/.
Mazurenko, S. V. (2020). Intellectual property in the field of medicines in the context of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Problems of legal regulation of civil relations in terms of Covid-19, 1, 50-58. In http://dspace.onua.edu.ua/handle/11300/12616.
Moskalyuk, N. B. (2013). Theoretical preconditions and practical aspects of parallel import in the system of realization of intellectual property rights to medicines. Journal of the Academy of Advocacy of Ukraine, 20(3), 1-6. In http://irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe?C21COM=2&I21DBN=UJRN&P21DBN=UJRN&IMAGE_FILE_DOWNLOAD=1&Image_file_name=PDF/Chaau_2013_3_16.pdf.
Musmann, T. (2020). German Government Plans Possibilities to Limit Patents In View of Corona Pandemic. Kluwer Patent Blog. In http://patentblog.kluweriplaw.com/2020/03/24/german-government-plans-possibilities-to-limit-patents-in-view-of-corona-pandemic/.
Orlova, А. (2019). Patent Strategies in Pharmaceuticals: Patent Greening. Journal of the Intellectual Property Rights Court, 26, 83-89. In http://ipcmagazine.ru/patent-law/patent-strategies-in-pharmaceuticals-patent-gardening.
PharmaTimes. (2013). Novartis loses Indian Glivec patent case. In http://www.pharmatimes.com/news/novartis_loses_indian_glivec_patent_case_1004741#:~:text=In%20a%20landmark%20case%2C%20the,requirements%20of%20India%27s%20patent%20law.
RBK Ukraine. (2020). A bill on criminal liability for overpricing of medicines to be submitted to the Rada. In https://www.rbc.ua/rus/news/radu-vnesut-zakonoproekt-ugolovnoy-otvetstvennosti-1584411554.html.
Research Institute of Intellectual Property of the National Academy of Legal Sciences of Ukraine. (2020). The committee of the Verkhovna Rada of Ukraine supports the bill on the implementation of the provisions of the EU legislation in the field of IP. In http://www.ndiiv.org.ua/index.php/ua/rada-molodykh-vchenykh/novyny/269-komitet-verkhovnoi-rady-ukrainy-pidtrymav-zakonoproekt-shchodo-implementatsii-zakonodavstva-yes-u-sferi-iv.
Senyuta, I. Ya. (2020). Processing of personal data under the new rules: protection or violation of human rights. Higher School of Advocacy NAAU. URL: https://www.hsa.org.ua/blog/obrobka-personalnyh-danyh-v-umovah-covid-19-zahyst-chy-porushennya-prav-lyudyny/.
Service, R. F. (2020). Would-be coronavirus drugs are cheap to make. Science. In https://www.sciencemag.org/news/2020/04/would-be-coronavirus-drugs-are-cheap-make.
Shcherbina, Y. (2009). How to break the collusion of doctors and pharmacists? UkrRudProm. In https://www.ukrrudprom.com/digest/Kak_razrushit_sgovor_
vrachey_i_farmatsevtov.html?print.
Shirsat, M.K. (2011). Drug Patent System in India and its Application. Asian Journal of Pharmaceutical and Clinical Research, 1(1), 13-24. In https://www.researchgate.net/publication/313860747_Drug_Patent_System_in_India_and_its_Application.
Shymkiv, D. (2020). The pharmaceutical industry is able to meet the needs of Ukrainians in medicines during a pandemic. UkrInform. In https://www.ukrinform.ru/rubric-economy/3014716-dmitrij-simkiv-predsedatel-soveta-direktorov-darnitsa-group.html.
Silverman, E. (2020). AbbVie will allow generic copies of its HIV pill in Israel after the government approved a license. Statnews. In https://www.statnews.com/pharmalot/2020/03/20/abbvie-israel-hiv-kaletra-coronavirus-covid19/.
Silverman, R. & Lusiani, N. (2020). Oxfam America People over profits: Make Covid-19 medicines and vaccines free and fair for all. Oxfam International. In https://www.oxfam.org/en/blogs/people-over-profits-make-covid-19-medicines-and-vaccines-free-and-fair-all.
Sparaciari, A. (2020). Coronavirus, a Brescia manca una valvola per i rianimatori: ingegneri e fisici la stampano in 3D in sei ore. Business insider Italia. In https://it.businessinsider.com/coronavirus-manca-la-valvola-per-uno-strumento-di-rianimazione-e-noi-la-stampiamo-in-3d-accade-nellospedale-di-chiari-brescia/.
Tomarov, I. (2020). Covid-19, respirators and patents for industrial designs. Vasyl Kisil Law Firm. In https://vkp.ua/ua/publication/covid-aparati-shtuchnogo-dikhannya-ta-patenti-na-promislovi-zrazki.
U.S. Government Accountability Office (GAO). (2017). Drug industry: Profits, Research and Development Spending, and Merger and Acquisition Deals. In https://www.gao.gov/products/GAO-18-40.
Ukraine. (1993). Fundamentals of Ukrainian Legislation on Health Care. In https://zakon.rada.gov.ua/laws/show/2801-12#Text.
Ukraine. (1993). On protection of rights to inventions and utility models: Law 3687-XII. In https://zakon.rada.gov.ua/laws/show/3687-12#Text.
Ukraine. (1993). On protection of rights to inventions and utility models: Law 3687-XII. In https://zakon.rada.gov.ua/laws/show/3687-12#Text.
Ukraine. (1994). On protection of industrial design rights: Law. In https://zakon.rada.gov.ua/laws/show/3688-12#Text.
Ukraine. (2018). On Amendments to Certain Legislative Acts of Ukraine Concerning the Implementation of Certain Provisions of European Union Legislation in the Field of Intellectual Property: Draft Law 9385. In http://search.ligazakon.ua/l_doc2.nsf/link1/JH78P00I.html.
Ukraine. (2020). On Amendments to Certain Laws of Ukraine Concerning the Treatment of Coronavirus Disease (Covid-19): Law 539-IX. In https://zakon.rada.gov.ua/laws/show/539-20#Text.
Ukraine. Cabinet of Ministers of Ukraine. (2004). On approval of the Procedure for granting permission by the to use a patented invention (utility model): Resolution. In https://zakon.rada.gov.ua/laws/show/8-2004-%D0%BF#Text.
Ukraine. Cabinet of Ministers. (2020). Some issues of procurement of goods, works and services necessary for the implementation of measures aimed at preventing the occurrence and spread, localization and elimination of outbreaks, epidemics and pandemics of acute respiratory disease Covid-19 caused by coronavirus SARS-CoV-2 in Ukraine: Resolution 225. In https://zakon.rada.gov.ua/laws/show/225-2020-%D0%BF#Text.
Ukraine. Economic Court of Kyiv. (2018). Judgment in case n° 910/4881/18. In https://verdictum.ligazakon.net/document/78650682.
Ukraine. National Police. (2019). Police expose a group of pharmaceutical companies in bribing doctors for 140 million hryvnias. Official Site of National Police. In https://www.npu.gov.ua/news/korupcziya/policziya-vikrila-grupu-farmaczevtichnix-kompanij-u-pidkupi-likariv-na-140-miljoniv-griven/%20.
United Nations (2008). Doha Declaration on Financing for Development: Outcome of the International Conference on the Follow-up to Financing for Development to Review Progress in the Implementation of the Monterrey Consensus. In https://www.un.org/ru/documents/decl_conv/declarations/doha_findev.shtml.
United States of America & Ukraine (1994). Treaty between Ukraine and the United States of America on the promotion and mutual protection of investments. In http://search.ligazakon.ua/l_doc2.nsf/link1/MU94065U.html.
USAID (2018). The results of the study “(Not)expensive medicine”. In https://docs.google.com/viewerng/viewer?url=http://patients.org.ua/wp-content/uploads/2017/03/free-medicine.pdf&hl=uk.
Wenzl, M. & Chapman, S. (2019). Performance-based managed entry agreements for new medicines in OECD countries and EU member states. How they work and possible improvements going forward. Health Working Papers OECD, 115, 4-5. In https://www.oecd.org/health/health-systems/HWP-115-MEAs.pdf.
World Health Organization (2005). Remuneration guidelines for non-voluntary use of a patent on medical technologies. In https://www.who.int/hiv/amds/WHOTCM2005.1_OMS.pdf.
World Intellectual Property Organization (1883). Paris Convention for the Protection of Industrial Property. In https://www.wipo.int/treaties/en/ip/paris/.
World Trade Organization (1994). Trade-Related Aspects of Intellectual Property Rights. In https://www.wto.org/english/tratop_e/trips_e/trips_e.htm.
Zaliska, O.M. & Stasiv, H.-O. I. (2019). “Managed access agreements” for innovative medicines to ensure the availability of drugs in European countries. Apteka. In https://www.apteka.ua/article/500494.
Zheltikhin, E. (2018). Antimonopoly Committee of Ukraine and the pharmaceutical market: pressure or protection? Legal Newspaper Online. In https://yur-gazeta.com/publications/practice/antimonopolne-konkurentne-pravo/amku-ta-farmrinok-tisk-chi-zahist.html.
Buletsa, S. B. (2020). Features of the contract of controlled access in the conditions of Covid-19. In http://dspace.onua.edu.ua/handle/11300/12616.
Canada. Supreme Court. (2017). AstraZeneca Canada Inc. v. Apotex Inc.: Judgment. In https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/16713/index.do.
Chepis, O. I. (2020). Ensuring the balance of interests of right holders and society in the application of compulsory licensing in the conditions of Covid-19. In http://dspace.onua.edu.ua/handle/11300/12616.
Chibisov, D. M. (2017). Protection of intellectual property rights within the World Trade Organization. Odesa: Phoenix. In http://hdl.handle.net/11300/7382.
Chirikhin, S. N. (2009). Is the rise in drug prices again the fault of the monopolies? All-Russian economic journal ECO, 1, 36-50. https://cyberleninka.ru/article/n/vzlet-tsen-na-lekarstva-opyat-vina-monopoliy/viewer.
Curia Europa (2020). PTC Therapeutics International v. EMA; MSD Animal Health Innovation and Intervet International v. EMA. In http://curia.europa.eu/juris/document/document_print.jsf?docid=222504&text=&dir=&doclang=EN&part=1&occ=first&mode=lst&pageIndex=0&cid=1853575.
Davis, M. M., Zimmerman, J. L., Wheeler, J. R. C. & Freed, F. L. (2002). Childhood Vaccine Purchase Costs in the Public Sector: Past Trends, Future Expectations. American Journal of Public Health, 92(12), 1982-1987. In https://www.immunize.ca/sites/default/files/resources/702e.pdf.
Delo.UA. (2016). Pharmacy chains create a monopoly, and 80% of drug supplies to Ukraine are controlled by 3 distributors. In https://delo.ua/business/aptechnye-seti-sozdajut-monopoliju-a-80-postavok-lekarstv-v-ukra-325399/.
Ennan, R.E. (2020). Methods of treatment as objects of patent law: world experience. Problems of legal regulation of civil relations in terms of Covid-19, 1, 41-45. In http://dspace.onua.edu.ua/handle/11300/12616.
European Commission (2001). Directive 2001/83/EC. In https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf.
European Parliament (2004). Regulation (EC) n° 726/2004. In https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32004R0726.
Ezekiel, L. E. (2019). Big Pharma’s Go-To Defense of Soaring Drug Prices Doesn’t Add Up. The Atlantic. In https://www.theatlantic.com/health/archive/2019/03/drug-prices-high-cost-research-and-development/585253/#:~:text=Many%20drugs%20cost%20more%20than,which%20there%20are%20definitive%20data.
Ferrario, A. & Kanavos, P. (2013). Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMiNet. 2013. In http://eprints.lse.ac.uk/50513/.
Ferrario, A., Araja, D., Bochenek, T., Catic, T., Danko, D., Dimitrova, M., Furst, J., Greiciute-Kuprijanov, I., Hoxha, I., Jakupi, A., Laidmae11, E., Loblova, O., ´ Mardare, I., Markovic-Pekovic, V., Meshkov, D., Novakovic, T., Petrova, G., Pomorski, M., Tomek, D., Voncina, L., Haycox, A., Kanavos, P., Bonanno, P.V., Godman, B. (2017). The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. PharmacoEconomics, 35(1). DOI 10.1007/s40273-017-0559-4.
Finland & Ukraine. (2004). Treaty between the Government of Ukraine and the Government of the Republic of Finland on the promotion and mutual protection of investments. In http://search.ligazakon.ua/l_doc2.nsf/link1/MU04261.html.
Gilead Sciences Inc. v. Ukraine. (1996). In https://arbitration.org/award/688.
Global Affairs Canada. (2013). Eli Lilly and Company v. Government of Canada. In https://www.international.gc.ca/trade-agreements-accords-commerciaux/topics-domaines/disp-diff/eli.aspx?lang=eng.
Gritsyk, A. R. & Stasiv, T. G. (2006). The method is the main object of patent law in the pharmaceutical industry. Problems of modern medical science, 1, 45-48.
Heckman, A. (2017). Supreme Court of Canada Rejects the Promise of the Patent Doctrine. Gowling WLG. In https://gowlingwlg.com/en/insights-resources/articles/2017/promise-of-the-patent-doctrine/.
Higgins-Dunn, N. (2020). House report accuses Trump administration of ‘waste, fraud or abuse’ in U.S. ventilator contract. CNBC. In https://www.cnbc.com/2020/07/31/coronavirus-house-report-accuses-trump-administration-of-waste-fraud-or-abuse-in-us-ventilator-contract.html.
In the Matter of C & W’s Application for a Patent. Reports of Patent. (1914). Design and Trade Mark Cases, Volume 31(9), 235-236. DOI 10.1093/rpc/31.9.235.
India. (1970). Patent Act. In http://ipindia.nic.in/writereaddata/Portal/ev/sections/ps3.html.
Interfax Ukraine. (2018). PJSC “Farmak” supported the resolution to support the draft law n° 9385. In https://interfax.com.ua/news/press-release/555670.html.
Interfax Ukraine. (2020). Top 10 largest pharmacy chains will consolidate up to 70% of the market over the next few years–forecast. In https://interfax.com.ua/news/pharmacy/666614.html.
Interfax-Ukraine. (2020). Compulsory licensing of drugs to combat coronavirus can be a “Pandora’s box” for the pharmaceutical market–a lawyer. In https://ua.interfax.com.ua/news/pharmacy/651558.html.
Jorge, M. (2020). Opinion: Big pharma is taking big money from U.S. taxpayers to find a coronavirus vaccine—and charge whatever they want for it. Market Watch. In https://www.marketwatch.com/story/big-pharma-is-taking-big-money-from-us-taxpayers-to-find-a-coronavirus-vaccine-and-charge-whatever-they-want-for-it-2020-06-24.
Joshi Attorneys. (2020). Changes in India’s Patent Law. In https://www.joshiattorneys.com/Cross-Border-And-International-Law-Topics/In-the-Shadows.shtml#:~:text=However%2C%20since%201970%2C%20India%20has,molecule % 20yields% 20a% 20new% 20patent.
Kaiser Family Foundation (2015). Most Say They Can Afford Their Prescription Drugs, But One in Four Say Paying is Difficult, Including More Than Four in Ten People Who are Sick. In https://www.kff.org/health-costs/press-release/most-say-they-can-afford-their-prescription-drugs-but-one-in-four-say-paying-is-difficult-and-more-than-four-in-ten-for-people-who-are-sick/.
Kashintseva, O. Y. (2017). Compulsory licensing of medicines: EU experience. Theory and practice of intellectual property, 3, 38-42. In http://www.inprojournal.org/wp-content/uploads/2017/10/Kashyntseva-O._317.pdf
Kharytonova, O. I. (2020). On the use of off-label drugs (out of instructions) and compassionate use (for reasons of humanity), Covid-19, and new opportunities and challenges in the context of intellectual property protection. In http://dspace.onua.edu.ua/handle/11300/12616.
Kirichenko, I. A. (2020). Forced import substitution, or where does TRIPS + lead? Lexology. In https://www.lexology.com/library/detail.aspx?g=fb95962d-a6d5-4b0a-b36f-63ae203c9f91.
Kirsanov, D. (2020). Pharmacy market of Ukraine. Helicopter View. In https://www.apteka.ua/article/531429.
Kuchler, H., Inagaki, K. & Neville, S. (2020). The global hunt for a coronavirus drug. Financial Times. In https://www.ft.com/content/91bd081e-6e7b-11ea-9bca-bf503995cd6f.
Kuzmenko, L.G. (2016). Parallel imports—an important mechanism for the existence of competitive relations. Scientific notes of NaUKMA. Economic Sciences, 1(1), 95-100. In http://ekmair.ukma.edu.ua/bitstream/handle/123456789/14668/Kuzmenko_Paralelnyi_import_vazhlyvyi_mekhanizm.pdf?sequence=1&isAllowed=y.
Kyrychenko, I. (2020). Parallel import as a portal to the parallel world. Apteka online. In https://www.apteka.ua/article/534838.
Lupkin, S. (2020). Prices for Covid-19 Vaccines are starting to come into Focus. Health News from NPR. In https://www.npr.org/sections/health-shots/2020/08/06/899869278/prices-for-covid-19-vaccines-are-starting-to-come-into-focus.
Marsh, T. (2020). Here’s How to Get Discounted (Or Even Free) Flu Shots This Year. Goodrx. In https://www.goodrx.com/blog/heres-how-to-get-discounted-or-even-free-flu-shots-this-year/.
Mazurenko, S. V. (2020). Intellectual property in the field of medicines in the context of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Problems of legal regulation of civil relations in terms of Covid-19, 1, 50-58. In http://dspace.onua.edu.ua/handle/11300/12616.
Moskalyuk, N. B. (2013). Theoretical preconditions and practical aspects of parallel import in the system of realization of intellectual property rights to medicines. Journal of the Academy of Advocacy of Ukraine, 20(3), 1-6. In http://irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe?C21COM=2&I21DBN=UJRN&P21DBN=UJRN&IMAGE_FILE_DOWNLOAD=1&Image_file_name=PDF/Chaau_2013_3_16.pdf.
Musmann, T. (2020). German Government Plans Possibilities to Limit Patents In View of Corona Pandemic. Kluwer Patent Blog. In http://patentblog.kluweriplaw.com/2020/03/24/german-government-plans-possibilities-to-limit-patents-in-view-of-corona-pandemic/.
Orlova, А. (2019). Patent Strategies in Pharmaceuticals: Patent Greening. Journal of the Intellectual Property Rights Court, 26, 83-89. In http://ipcmagazine.ru/patent-law/patent-strategies-in-pharmaceuticals-patent-gardening.
PharmaTimes. (2013). Novartis loses Indian Glivec patent case. In http://www.pharmatimes.com/news/novartis_loses_indian_glivec_patent_case_1004741#:~:text=In%20a%20landmark%20case%2C%20the,requirements%20of%20India%27s%20patent%20law.
RBK Ukraine. (2020). A bill on criminal liability for overpricing of medicines to be submitted to the Rada. In https://www.rbc.ua/rus/news/radu-vnesut-zakonoproekt-ugolovnoy-otvetstvennosti-1584411554.html.
Research Institute of Intellectual Property of the National Academy of Legal Sciences of Ukraine. (2020). The committee of the Verkhovna Rada of Ukraine supports the bill on the implementation of the provisions of the EU legislation in the field of IP. In http://www.ndiiv.org.ua/index.php/ua/rada-molodykh-vchenykh/novyny/269-komitet-verkhovnoi-rady-ukrainy-pidtrymav-zakonoproekt-shchodo-implementatsii-zakonodavstva-yes-u-sferi-iv.
Senyuta, I. Ya. (2020). Processing of personal data under the new rules: protection or violation of human rights. Higher School of Advocacy NAAU. URL: https://www.hsa.org.ua/blog/obrobka-personalnyh-danyh-v-umovah-covid-19-zahyst-chy-porushennya-prav-lyudyny/.
Service, R. F. (2020). Would-be coronavirus drugs are cheap to make. Science. In https://www.sciencemag.org/news/2020/04/would-be-coronavirus-drugs-are-cheap-make.
Shcherbina, Y. (2009). How to break the collusion of doctors and pharmacists? UkrRudProm. In https://www.ukrrudprom.com/digest/Kak_razrushit_sgovor_
vrachey_i_farmatsevtov.html?print.
Shirsat, M.K. (2011). Drug Patent System in India and its Application. Asian Journal of Pharmaceutical and Clinical Research, 1(1), 13-24. In https://www.researchgate.net/publication/313860747_Drug_Patent_System_in_India_and_its_Application.
Shymkiv, D. (2020). The pharmaceutical industry is able to meet the needs of Ukrainians in medicines during a pandemic. UkrInform. In https://www.ukrinform.ru/rubric-economy/3014716-dmitrij-simkiv-predsedatel-soveta-direktorov-darnitsa-group.html.
Silverman, E. (2020). AbbVie will allow generic copies of its HIV pill in Israel after the government approved a license. Statnews. In https://www.statnews.com/pharmalot/2020/03/20/abbvie-israel-hiv-kaletra-coronavirus-covid19/.
Silverman, R. & Lusiani, N. (2020). Oxfam America People over profits: Make Covid-19 medicines and vaccines free and fair for all. Oxfam International. In https://www.oxfam.org/en/blogs/people-over-profits-make-covid-19-medicines-and-vaccines-free-and-fair-all.
Sparaciari, A. (2020). Coronavirus, a Brescia manca una valvola per i rianimatori: ingegneri e fisici la stampano in 3D in sei ore. Business insider Italia. In https://it.businessinsider.com/coronavirus-manca-la-valvola-per-uno-strumento-di-rianimazione-e-noi-la-stampiamo-in-3d-accade-nellospedale-di-chiari-brescia/.
Tomarov, I. (2020). Covid-19, respirators and patents for industrial designs. Vasyl Kisil Law Firm. In https://vkp.ua/ua/publication/covid-aparati-shtuchnogo-dikhannya-ta-patenti-na-promislovi-zrazki.
U.S. Government Accountability Office (GAO). (2017). Drug industry: Profits, Research and Development Spending, and Merger and Acquisition Deals. In https://www.gao.gov/products/GAO-18-40.
Ukraine. (1993). Fundamentals of Ukrainian Legislation on Health Care. In https://zakon.rada.gov.ua/laws/show/2801-12#Text.
Ukraine. (1993). On protection of rights to inventions and utility models: Law 3687-XII. In https://zakon.rada.gov.ua/laws/show/3687-12#Text.
Ukraine. (1993). On protection of rights to inventions and utility models: Law 3687-XII. In https://zakon.rada.gov.ua/laws/show/3687-12#Text.
Ukraine. (1994). On protection of industrial design rights: Law. In https://zakon.rada.gov.ua/laws/show/3688-12#Text.
Ukraine. (2018). On Amendments to Certain Legislative Acts of Ukraine Concerning the Implementation of Certain Provisions of European Union Legislation in the Field of Intellectual Property: Draft Law 9385. In http://search.ligazakon.ua/l_doc2.nsf/link1/JH78P00I.html.
Ukraine. (2020). On Amendments to Certain Laws of Ukraine Concerning the Treatment of Coronavirus Disease (Covid-19): Law 539-IX. In https://zakon.rada.gov.ua/laws/show/539-20#Text.
Ukraine. Cabinet of Ministers of Ukraine. (2004). On approval of the Procedure for granting permission by the to use a patented invention (utility model): Resolution. In https://zakon.rada.gov.ua/laws/show/8-2004-%D0%BF#Text.
Ukraine. Cabinet of Ministers. (2020). Some issues of procurement of goods, works and services necessary for the implementation of measures aimed at preventing the occurrence and spread, localization and elimination of outbreaks, epidemics and pandemics of acute respiratory disease Covid-19 caused by coronavirus SARS-CoV-2 in Ukraine: Resolution 225. In https://zakon.rada.gov.ua/laws/show/225-2020-%D0%BF#Text.
Ukraine. Economic Court of Kyiv. (2018). Judgment in case n° 910/4881/18. In https://verdictum.ligazakon.net/document/78650682.
Ukraine. National Police. (2019). Police expose a group of pharmaceutical companies in bribing doctors for 140 million hryvnias. Official Site of National Police. In https://www.npu.gov.ua/news/korupcziya/policziya-vikrila-grupu-farmaczevtichnix-kompanij-u-pidkupi-likariv-na-140-miljoniv-griven/%20.
United Nations (2008). Doha Declaration on Financing for Development: Outcome of the International Conference on the Follow-up to Financing for Development to Review Progress in the Implementation of the Monterrey Consensus. In https://www.un.org/ru/documents/decl_conv/declarations/doha_findev.shtml.
United States of America & Ukraine (1994). Treaty between Ukraine and the United States of America on the promotion and mutual protection of investments. In http://search.ligazakon.ua/l_doc2.nsf/link1/MU94065U.html.
USAID (2018). The results of the study “(Not)expensive medicine”. In https://docs.google.com/viewerng/viewer?url=http://patients.org.ua/wp-content/uploads/2017/03/free-medicine.pdf&hl=uk.
Wenzl, M. & Chapman, S. (2019). Performance-based managed entry agreements for new medicines in OECD countries and EU member states. How they work and possible improvements going forward. Health Working Papers OECD, 115, 4-5. In https://www.oecd.org/health/health-systems/HWP-115-MEAs.pdf.
World Health Organization (2005). Remuneration guidelines for non-voluntary use of a patent on medical technologies. In https://www.who.int/hiv/amds/WHOTCM2005.1_OMS.pdf.
World Intellectual Property Organization (1883). Paris Convention for the Protection of Industrial Property. In https://www.wipo.int/treaties/en/ip/paris/.
World Trade Organization (1994). Trade-Related Aspects of Intellectual Property Rights. In https://www.wto.org/english/tratop_e/trips_e/trips_e.htm.
Zaliska, O.M. & Stasiv, H.-O. I. (2019). “Managed access agreements” for innovative medicines to ensure the availability of drugs in European countries. Apteka. In https://www.apteka.ua/article/500494.
Zheltikhin, E. (2018). Antimonopoly Committee of Ukraine and the pharmaceutical market: pressure or protection? Legal Newspaper Online. In https://yur-gazeta.com/publications/practice/antimonopolne-konkurentne-pravo/amku-ta-farmrinok-tisk-chi-zahist.html.
Published
2020-10-15
How to Cite
Fedorov, V., Kravchenko, S., Reznichenko, H., Opara, N., & Tsybokhin, O. (2020). Theoretical Problems of Legal Regulation of Innovations in the Medical Field: Experience in Counteracting Covid-19. Ius Humani. Law Journal, 9(2), 251-289. https://doi.org/https://doi.org/10.31207/ih.v9i2.254
Section
Papers
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors publishing in our Journal comply to the following terms:
1. Authors keep their work’s copyrights, but they guarantee Ius Humani Law Journal to be the first publisher of their papers. They grant the Journal will a Creative Commons Attribution License, under which their work can be shared with the condition that it is appropriately cited.
2. Authors are aware and accept that the Ius Humani Team will try to give the greatest diffusion to the Journal, which means, among other things, that its printed and electronic editions will be distributed among different databases and scientific indexes.
3. Authors can establish further clauses for non exclusive distribution, such as publication on a separate book or placing in an institutional data-base. Nevertheless, a note should be always added to explain that the paper was originally published in Ius Humani Law Journal.
4. We permit and encourage authors to share their work through Internet before and during the editorial process to receive further recommendations and wider references (we recommend you read the article The Effect of Open Access).
